Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05369832 · ClinicalTrials.gov registry record · Phase 4
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 4
- Development phase
- 139
- Enrollment target
NCT05369832 is a Phase 4 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 139 participants.
The verdict
NCT05369832, a Phase 4 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 139 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
Interventions
- DRUG Ozanimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2025-04-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05369832
The ClinicalTrials.gov registry entry for NCT05369832 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ozanimod is the first listed.
NCT05369832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05369832 about?
NCT05369832 is a clinical study titled "An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice". The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
What is the current status of trial NCT05369832?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 139 participants. The study started on 2022-12-16. Estimated completion is 2025-04-11.
What interventions are being tested in trial NCT05369832?
The interventions under investigation include: Ozanimod (DRUG).
Who is sponsoring clinical trial NCT05369832?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.